Skip to main content
logo
Quince Therapeutics, Inc. (QNCX)
NASDAQ: QNCX · Real-Time Price · USD
32.15
+0.04 (0.12%)
Sep 2, 2026, 4:00 PM EDT - Market closed

Quince Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Market Capitalization
33187824523377
Market Cap Growth
-61.95%126.70%82.80%95.46%-93.89%-53.99%
Enterprise Value
-8317850-38-71264
Last Close Price
32.15670.00374.00210.00127.482524.00

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PB Ratio
0.30-5.222.730.530.233.18
P/TBV Ratio
---11.890.243.18

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
--0.520.490.160.010.01
Net Debt / Equity Ratio
-1.07-0.02-0.86-0.72-0.89-0.89
Net Debt / EBITDA Ratio
1.91-0.010.722.521.801.17
Net Debt / FCF Ratio
2.47-0.020.813.322.031.67
Quick Ratio
14.230.495.737.9529.717.59
Current Ratio
14.520.536.058.0930.557.85
Return on Equity (ROE)
-153.84%--98.63%-33.81%-47.14%-61.85%
Return on Assets (ROA)
-31.51%-30.31%-16.01%-11.33%-26.40%-34.99%
Return on Capital Employed (ROCE)
-52.60%-100.30%-33.70%-15.60%-49.70%-75.90%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-282.81%-45.02%-69.06%-69.73%-224.32%-23.86%
FCF Yield
-143.74%-22.40%-39.09%-40.99%-191.80%-16.74%
Buyback Yield / Dilution
-704.22%-15.80%-16.18%-11.17%-12.71%-1.86%
SEC Filings: 10-K · 10-Q